VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Registration Number
- NCT00063713
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Brief Summary
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
- Detailed Description
VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 152
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (34)
University of Alabama
🇺🇸Birmingham, Alabama, United States
UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Georgetown University Medical Center Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
The Rush Cancer Center
🇺🇸Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
University Hospital-Madison Wisconsin
🇺🇸Madison, Wisconsin, United States
Loma Linda Cancer Research Institute
🇺🇸Loma Linda, California, United States
University of Colorado Cancer
🇺🇸Denver, Colorado, United States
Alta Bates Medical Center
🇺🇸Berkeley, California, United States
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
The Emory Clinic
🇺🇸Atlanta, Georgia, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Indiana University Cancer Center
🇺🇸Indianapolis, Indiana, United States
North Memorial Hospital
🇺🇸Robbinsdale, Minnesota, United States
Onc/Hem Associates of Kansas City
🇺🇸Kansas City, Missouri, United States
University of Iowa Hospital Division
🇺🇸Iowa City, Iowa, United States
New York Hospital Cornell Medical Center
🇺🇸New York, New York, United States
Beth Israel Medical Center
🇺🇸New York, New York, United States
St Lukes-Roosevelt Hospital
🇺🇸New York, New York, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Wake Forest, University health Sciences/Comprehensive Cancer Center
🇺🇸Winston-Salem, North Carolina, United States
Oregon Health Science University
🇺🇸Portland, Oregon, United States
Vanderbilt University
🇺🇸Nashville, Tennessee, United States
Cancer Care Associates
🇺🇸Tulsa, Oklahoma, United States
University of Pennsylvania Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Western Pennsylvania Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Sarah Cannon Cancer Center
🇺🇸Nashville, Tennessee, United States